PARP Inhibitors for Prostate Cancer: 5 Things to Know Kate O'Rourke

https://www.medscape.com/viewarticle/parp-inhibitors-prostate-cancer-5-things-know-2026a1000ocr?src= Prostate cancer is the second most common cancer in men worldwide, with nearly 1.4 million new cases diagnosed each year. PARP inhibitors have transformed the treatment landscape for biomarker‑selected metastatic disease, moving from experimental agents to a core option for a subset of men with advanced prostate cancer. By exploiting defects in DNA repair — particularly homologous recombination repair (HRR) alterations such as BRCA1 and BRCA2 — these drugs can deliver meaningful survival gains after progression on standard hormone‑directed therapies. But their use is not one size fits all: benefit depends on tumor genomics, indications remain restricted to metastatic settings, and class‑specific toxicities such as anemia demand close monitoring and dose adjustment.